2004D-0042 - Draft Guidance for Industry on Improving Information About Medical Products and Health Conditions; Withdrawal; Availability
FDA Comment Number : EC14
Submitter : Mr. David McAvoy Date & Time: 09/16/2004 06:09:03
Organization : Eli Lilly and Company
Drug Industry
Category :
Issue Areas/Comments
Eli Lilly and Company wishes to submit to the public docket separate written comments on the FDA draft guidances for communicating risk information in consumer prints ads and for help-seeking ads. Lilly has just completed a research study on disclosure of print ads and received the results only as of August 6. Lilly has completed a preliminary analysis of these data and will submit written comments tonight; however, we are experiencing technical difficulties with our company's computer network. We anticipate still submitting these comments by midnight, August 10 (EST). As for the Lilly help-seeking ad comments, these will be submitted by close of business, August 13.